drugset / Trial / NCT02010775
Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the safety and efficacy of a range of doses of botulinum toxin Type A (BOTOX®) for the treatment of patients with bilateral Masseter Muscle Hypertrophy (MMH).
Timeline
- Start
- 2014-01-20
- Primary completion
- 2017-03-07
- Completion
- 2017-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 24 iu | Intramuscular |
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 48 iu | Intramuscular |
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 72 iu | Intramuscular |
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 96 iu | Intramuscular |